-
Analysis: The current research status of the clinical application of musk and its substitutes
Time of Update: 2021-03-08
So, according to the specific application, the selection of suitable musk substitutes is conducive to the long-term development of the industry, the current alternatives to musk are mainly Chinese herbal medicine, animals, synthetic and artificial cultured musk.
-
BMS acquires new base results: 121 amines sold since 2020...
Time of Update: 2021-03-08
On February 04, 2021, Shishi Shiguibao released its 2020 results, the first since the completion of its acquisition of Celgene, which reported full-year revenue of $42.5 billion, up 63%; the most no
-
Microcore Biology: Theo Ronnie Capsules Approved for Clinical Trials
Time of Update: 2021-03-08
Phase II clinical study of platinum-difficult/platinum-resistant recurrence ovarian cancer with combined chemotherapy showed good patient tolerance, with the main side effects associated with the mechanism of action and no heart-related toxicity observed.
-
12 new class 1 drug batch clinical, from Sanofi, Yingpai Pharmaceuticals and other companies | Cde...
Time of Update: 2021-03-08
May 2020, the drug has been approved clinically in the United States for the treatment of IDH1 mutations in solid tumors including advanced bile tube cancer, cartilage sarcoma and glioma.
-
East China Medicine heavy-handedly hit the medical U.S. track, the future transformation depends on it?
Time of Update: 2021-03-07
, as early as 2013, East China Medicine took the chinese rights and interests of Uric acid Yiwan to enter the field of medical beauty, began a new layout.
-
10 domestic 1 class of new drugs "on the market take off"! It's sunny, Hengrui, Howson bright...
Time of Update: 2021-03-07
Amedini is the world's second third-generation EGFR-TKI innovative drug, and the first domestic third-generation EGFR-TKI drug, approved for sale in China on March 31, 2020 for the treatment of EGFR mutation non-small cell lung cancer, the main sales channels in retail pharmacy terminals, the full-year 2020 forecast sales of more than 130 million yuan.
-
(..)
Time of Update: 2021-03-07
to study the relationship between the use of glucose by tumor cells and the response to immunotherapy, the researchers used a highly sugar-ionized mouse model of breast cancer --- which means it uses a lot of sugar to grow.
-
18F-FET PET identifies the value of glioma progression
Time of Update: 2021-03-06
October 2017 MRI-T2 axle (A.left) and T1 enhanced axon (A.right); November 18, 2017 F-FET PET (B); and November 2017 biopsy sample histology (Sumu-Ihong (C) and immunologic chemistry (IDH1_R132H, arrows indicating IDH1_R132H positive tumor cells) (D).
-
Postoperative ancillary treatment of esophageal cancer/gastroesophageal cancer! Pepsi Opdivo receives FDA Priority Review: Significantly Extending Disease-Free Survival!
Time of Update: 2021-03-06
Jan. 20, 2021 // -- BMS recently announced that the U.S. Food and Drug Administration (FDA) has accepted the anti-PD-1 therapy Opdivo (Odi) Waugh, generic name: nivolumab, Navuliyu mono-anti) A supplementary biological product licensing application (sBLA), which seeks approval for Opdivo for complementary treatment of adult patients with esophageal or gastroesophageal connection (GEJ) cancer who have undergone new assisted chemotherapy (CRT) and excision.
-
JAMA Network Open: Chinese scientists have developed a new deep learning technique that promises to successfully predict hidden peritometrial metastasis in patients with stomach cancer!
Time of Update: 2021-03-06
January 11, 2021 // -- Stomach cancer is a common gastrointestinal malignancies that often occur in most patients with advanced stomach cancer, which is considered an invasive cancer and often has a p
-
The response of super mutant gliomas to immuno-checkpoint inhibitors is heterogeneic
Time of Update: 2021-03-06
Blocking immune checkpoints such as PD-1 and CTLA-4 can reduce inhibition of T cells, restore T-cell activation and proliferation, and reactivate anti-tumor immunity. point-of-immune checkpoint inhi
-
Nat Metabol: Scientists hope to develop a new potential treatment for malignant non-small cell lung cancer
Time of Update: 2021-03-06
Weakness ( metabolic vulnerability ) , the results of the study may help develop new therapies to treat cancer patients with mutations in the KRAS and LKB1 genes , which tend to have poor prognosis and are not usually responsive to immunotherapy .
-
A global survey of machine learning applications in neurosurgery
Time of Update: 2021-03-05
The study analyzed an overview of ML's use in global neurosurgery, which can better interpret imaging data, predict prognosis and complications, improve patients' quality of life and surgical satisfaction, and improve diagnostic and surgical decision-making.
-
A study of the heavyweight highlights that Nature had to look at in January
Time of Update: 2021-03-05
doi:10.1038/s41586-020-03057-ydoi:10.1038/d41586-020-03577-In a recent study published in the international journal Nature, scientists from institutions such as the Albert Einstein College of Medicine found that pain nerves in the body's bone marrow may help regulate the mobilization of hematopoietic stem cells.
-
Scientists have made new progress in the field of cancer metastasis and spread!
Time of Update: 2021-03-05
article, the editor summarizes recent advances in the field of cancer metastasis research and learns from them! Photo credit: Cancer Cell, 2020, doi:10.1016/j.ccell.2020.10.004(1) Cancer Cell: Reveal
-
Nat Immunol: Sugar and fat play the opposite role in cancer cell immunotherapy
Time of Update: 2021-03-05
results of the study were published online January 18, 2021 in the journal Nature Immunology under the title "Distinct metabolic programs established in the thymus control effector functions of the "T cell subsets in tumor microenvironment." author daniel J.
-
How scientists have succeeded in mapping what promises to improve the study of many human diseases!
Time of Update: 2021-03-05
Doi:10.1038/s41586-020-2969-2 Recently, in a study published in the international journal Nature entitled "A metastasis map of human cancer cell lines", scientists from the Broad Institute and other institutions in the United States have successfully mapped the metastasis of human cancer cell lines, the results of which may help clarify the metastasis of cancer and the development of new therapies to prevent cancer metastasis and cancer treatment.
-
Professor Chen Minshan: IMbrave150 research re-weight results, China sub-group OS breakthrough 24 months!
Time of Update: 2021-03-05
to this, the doctor had the honor to interview Professor Chen Minshan, Director of Liver Surgery at Sun Yat-sen University Cancer Prevention and Control Center and Director of the Institute of Liver Cancer research at Sun Yat-sen University, to introduce the advantages of immuno combination therapy in liver cancer treatment and the new direction of future exploration.
-
CD19 CAR-T Cell Therapy! The first three total Yescarta was approved in Japan: treatment of recurrence / incurable large B cell lymphoma!
Time of Update: 2021-03-04
January 26, 2021 // -- Daiichi Sankyo recently announced that Japan's Ministry of Health, Labour (MHLW) has approved Yescarta (axicabtagene ciloleucel), a CD19-guided chiline antigen (CAR) T-cell therapy for the treatment of certain relapsed/refractic large B-cell lymphoma (LBCL) adults.
-
Bladder cancer is heavy! EU approves Merck/Pfizer immunotherapy Bavencio for first-line maintenance therapy: will change clinical practice!
Time of Update: 2021-03-04
January 26, 2021 // -- Merck KGaA and partner Pfizer recently jointly announced that the European Commission (EC) Anti-PD-L1 therapy Bavencio (avelumab) has been approved as a single-drug therapy for
